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Abstract 
Purpose:  Estimating the rate of adverse events (AEs) caused by a treatment in clinical trials 
typically involves comparing the proportions of patients experiencing AEs in intervention 
and control groups. However potentially important information, including duration, 
recurrence, and intensity of events, is lost. In this study we illustrate how the additional 
information can be obtained and incorporated into analyses of AEs.  
Methods: Data on psychiatric AEs were extracted from clinical study reports (CSRs) 
provided by the manufacturer of oseltamivir in four prophylaxis randomised trials in adults 
and adolescents. We analysed the incidence, recurrence, duration and intensity of events, 
using logistic regression models where the outcome compared was proportion of days 
suffering from an event, and developed novel presentation techniques.  
Results: Psychiatric adverse events were generally more frequent, longer and more intense in 
the treatment than placebo arms. Logistic regression models confirm the apparent association 
overall (odds ratio [OR] 3.46, 95% confidence interval [CI] 1.28 to 9.32), particularly for 
events classified as severe (OR 34.5, 95% CI 3.66 to 325). However, the absolute difference 
in proportion of days suffering from severe psychiatric adverse events between groups was 
small.  
Conclusions: This example analysis shows evidence of a causal effect of oseltamivir on 
psychiatric AEs, not apparent in the published versions of the same trials and a Cochrane 
review which showed a non-significant 81% increased odds of experiencing a psychiatric 
event. This unique and important finding was dependent on obtaining previously unavailable 
data from clinical study reports and using novel analyses and presentation methods.  
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Key points:  
There has been much scientific debate on whether oseltamivir plays a causal role in the 
development of psychiatric adverse events.  
Using detailed previously unavailable data obtained from clinical study reports of 
prophylaxis trials and novel statistical and graphical methods we show evidence of a causal 
effect of oseltamivir on psychiatric adverse events.  
The increase in absolute risk of experiencing a psychiatric adverse event is small 
We believe our methods can be used more generally to provide new insights into the 
unintended effects of pharmaceutical interventions. 
  
Introduction 
Oseltamivir [TamifluR] is a neuraminidase inhibitor approved by the US Food and Drug 
Administration (FDA) in 1999 for treating and preventing influenza. Many governments 
across the world stockpiled oseltamivir after 2005 in response to a potential influenza 
pandemic so that hundreds of thousands of doses of oseltamivir could have been administered 
quickly if necessary(1).  
In 2007 Japan banned oseltamivir use in teenagers because of observed abnormal behaviour 
causing accidental deaths in those administered the drug(2). In 2008, the manufacturer 
reviewed oseltamivir’s safety, reporting significantly fewer patients randomised to the drug 
(12/1662; 0.7%) had neuropsychiatric AEs compared to placebo (20/1128; 1.8%; p < 0.05) in 
prophylaxis trials, citing “data on file”(3). A 2009 Cochrane systematic review of published 
trials, found no evidence of neuropsychiatric AEs in the trials (4) however a 2014 Cochrane 
update review, now including previously unpublished clinical study reports (CSRs), reported 
a statistically non-significant increase in psychiatric on-treatment AEs in four prophylaxis 
trials (relative risk [RR] 1.81, 95% confidence interval [CI]: 0.97 to 3.37), and a statistically 
significant increase in neurological on-treatment AEs (RR 1.21 , 95% CI: 1.03, 1.42)(5).   
CSRs are produced by pharmaceutical companies for regulators as part of the drug approval 
process and have been available since 2010 to independent researchers through the European 
Medicines Agency (EMA) as well as directly by some pharmaceutical companies. They 
contain more detailed information than publications, including duration and severity of AEs, 
otherwise not available(6), and should be analysed where possible to report the additional 
details(7). Use of this additional important source of information has been limited to date (5).  
There are other reasons to exploit CSRs more: simple comparison of proportions of patients 
with AEs can be misleading because of recurrent AEs, and unequal follow up periods(8). 
Intensity of AEs is also not assessed in a simple comparison of proportions of patients 
reporting AEs. Accordingly, we capitalise on the additional information in CSRs to better 
explore the full extent of psychiatric AEs associated with prophylactic use of oseltamivir, 
addressing many of the several weaknesses of a naive analysis. This required us to develop 
new methods because of the paucity of prior experience of analysing information in CSRs. 
Methods 
Selection of studies: We included all prophylaxis randomised studies of oseltamivir compared 
to placebo where a CSR was available, using prophylactic trials because of their increased 
patient surveillance time and because the psychiatric AEs reported were less likely to be 
attributed to influenza-like-illness when patients were influenza free at baseline, Table 1.  
Data sources: CSRs were supplied by the manufacturer of oseltamivir in 2013 after an open 
data campaign initiated by the British Medical Journal (www.bmj.com/tamiflu). Prior to 2013 
some incomplete CSRs had been received from the EMA. Information available from the 
reports in relation to oseltamivir use included duration, intensity, the relationship of adverse 
events (AEs) to medication as judged by study investigators, day of initiation, Medical 
Dictionary for Regulatory Activities (MedDRA) preferred term (e.g. ‘nausea’) for each AE, 
and the patients: gender, treatment group assignment, dates of starting and ending treatment, 
and age (Box). Data was extracted by MJ and independently checked by CDM. We only 
included on-treatment events classified in the CSRs under the “psychiatric” system organ 
class and did not recode or reclassify events, apart from two in trial WV15825 that were 
originally misclassified but subsequently corrected (9). The CSRs used for this analysis are 
available at http://datadryad.org/resource/doi:10.5061/dryad.77471, (accessed 17 May 2017). 
Adverse events were defined in the clinical trials as any change from the patient’s baseline 
condition which occurred during the trial after treatment began irrespective of whether it was 
thought to be related to the study treatment. Symptoms of influenza were not counted as 
adverse events unless they fulfilled the criteria for serious adverse events. Exact timing on 
when information was obtained from patients on adverse events throughout the follow up 
period differed between studies, Table 1. Information on AEs was obtained via patient 
interview and recorded onto standardised AE case report forms. Any unresolved adverse 
events at the end of the study were followed up until they were either resolved or until an 
explanation was obtained as to why no end date was available. Further detail on the 
information collected on adverse events for each clinical trial is available in the blank case 
report forms contained in Module 2 of the CSRs (see complete data, referenced above, for 
access).  
Statistical methods: We compared the proportion of days patients suffered from psychiatric 
AEs between trial groups. For example, a patient with depression for 10 days and 
subsequently anxiety for 5 days over the 8 week follow up would have 15/56 days suffering 
from psychiatric adverse events. This accounts for multiple AEs, as well as their duration, 
which is not possible if a simple dichotomy between proportions of patients affected is used.  
We analysed the data using single stage individual patient meta-analysis via logistic 
regression models(10). Differences in AE rates between trials (possibly due to differences in 
baseline demographics such as age or differences in follow up duration) were accounted for 
by including a categorical variable in the models indicating each trial data; and a variable in 
the model tested the interaction between trial and treatment group on the outcome. Intensity 
of the AE was incorporated into a second analysis by using weighted nominal logistic 
regression, with weights and outcome based on the number of days the patient suffered from 
each of severe, moderate, mild and no psychiatric adverse event. As the unit of analysis was 
days within patients, we estimated cluster robust standard errors to account for repeated 
measures where each patient was a cluster.  
Percentages of days affected by psychiatric AEs by intensity were estimated from predicted 
probabilities obtained from the weighted nominal logistic regression model. We also 
estimated number of patient days of treatment that would lead to one additional day of 
suffering from a psychiatric AE of any intensity. We did this by subtracting the estimated 
proportion of days affected by psychiatric AEs in the placebo group from that of the 
treatment group and then taking the reciprocal of this value. We also made an adjustment to 
account for most patients being treated for 6 weeks but followed up for a further 2 weeks.   
One of the trials (WV15673/97) included three treatment groups: placebo, oseltamivir 75 mg 
o.d., or oseltamivir 75 mg b.i.d. for 6 weeks. For the main analysis we combined the two 
oseltamivir groups however in an additional analysis we investigated the dose response effect 
of oseltamivir in trial WV15673/97 using logistic regression with the explanatory variable 
treatment group coded as -1 (placebo), 0 (oseltamivir 75 mg o.d.), or 1 (oseltamivir 75 mg 
b.i.d.).  
In addition to the statistical analysis we present plots of the psychiatric adverse events over 
the follow up of the studies for individual patients. For each patient with an event, a 
horizontal line segment shows day of initiation as well as duration of the event. Intensity is 
illustrated using different line styles and events unresolved at the end of the follow up are 
indicated using hollow circles. Multiple events within patients can be shown using multiple 
line segments and numbers of patients with events are shown on the y-axis. Plots are 
stratified by treatment group with numbers of patients contributing to safety assessment 
provided next to the treatment group labels.  
Results 
AEs in the treatment group were more frequent and severe, of longer duration, and possibly 
of earlier occurrence, than in the placebo group in the three prophylaxis trials of 6 weeks of 
treatment with oseltamivir for individuals exposed to influenza, Figures 1 & 2. A post-
exposure prophylaxis trial, WV15799, where exposure to medication was for only 7 days, 
had few events, Figure 3. There were 13 types of AEs reported in the four clinical trials 
(classified by MedDRA preferred terms), Table 2.  
The proportion of days patients suffered from a psychiatric adverse event was greater in 
oseltamivir groups, odds ratio (OR) 3.46 (95% confidence interval [95% CI] 1.28 to 9.32). A 
test for interaction between trial and outcome showed evidence (P=0.01) that WV15799 had a 
different treatment effect on AEs than the other three trials, with an OR at <1.  If WV15799 is 
excluded from the analysis, the OR increases from 3.46 to 4.12 (95% CI 1.40 to 12.1). 
Analysing the intensity of the AEs showed little difference between groups (OR 1.23, 95% CI 
0.30 to 5.04) for mild AEs, but a statistically non-significant increase for moderate AEs (OR 
4.34, 95% CI 0.79 to 24.0), and a large, significant increase for severe AEs (OR 34.5, 95% CI 
3.66 to 325). However, the predicted proportions of days affected by psychiatric adverse 
events from the weighted nominal logistic model, illustrating the absolute differences 
between groups, are small, Table 3. 
In the additional analysis of trial WV15673/97 there was insufficient evidence of a dose-
response effect of oseltamivir on proportion of days patients suffered from a psychiatric 
adverse event, odds ratio (OR) 1.30 (95% confidence interval [95% CI] 0.74 to 2.27). 
Discussion 
We found patients using oseltamivir had a greater than 3-fold increased odds of suffering 
from a psychiatric AE compared to those using placebo, most notably for events with severe 
intensity, suggesting a causal effect. Although the relative effect is very high for severe 
events, the absolute increase is small when considered in the context of all patients included 
in the study over the 3-8 week follow up periods. The effect was consistent over the three 
trials where exposure to treatment was 6 weeks long, but not for the one study, where 
exposure was for only 1 week, perhaps because of the reduced exposure, reduced follow up, 
or insufficient power to discern enough AEs. There was insufficient evidence of a dose-
response effect of treatment on odds of suffering from a psychiatric AE however this analysis 
was only able to be performed using one trial hence power is low.     
One important limitation of this research is that children were not included in any of the trials 
(despite oseltamivir being approved by the FDA for treatment prophylaxis for patients aged 
≥1 year). Clearly, the definition of ‘neuropsychiatric adverse event’ is critical. The different 
conclusions between the manufacturer sponsored report and the Cochrane review is 
attributable to the manufacturer (in consultation with the FDA) creating a post-hoc definition 
for neuropsychiatric adverse events while the original classifications reported in the CSRs for 
psychiatric and neurological adverse events were maintained for the current study and the 
Cochrane review(11).  
Perhaps even more important than these findings specific to oseltamivir is our use of novel 
methods based on using CSRs. Obtaining access to these documents has allowed us to 
conduct very detailed analyses far beyond what is possible with conventional published trials, 
allowing us to incorporate important information only available in the CSRs, including 
multiple events suffered by individual patients, duration of events, and the intensity of events. 
Some of the data used for this study had been previously extracted from CSRs for a 
systematic review of neuraminidase inhibitors (5). Data extraction was somewhat labour 
intensive however CSRs are required to conform to a reporting standard(12) and the 
oseltamivir CSRs were relatively easy to navigate around once familiarity of the format had 
been attained. In future work we plan to investigate whether AE data from CSRs can be 
converted from pdf format to electronic spreadsheet format to facilitate full analysis of all AE 
data contained in CSRs.         
This study illustrates the importance of transparency of clinical trial data. Transparency can 
be improved with public access to clinical study reports. This has already occurred to some 
degree with the EMA releasing CSRs to independent researchers on request since November 
2010(13). Furthermore the EMA began proactively publishing CSRs submitted as part of 
marketing-authorisation applications for human medicines in 2016 and, in a second phase, 
plan to release de-identified individual patient data (IPD)(14). Recently the FDA has 
implemented a pilot study to trial the release of CSRs (15) and some pharmaceutical 
companies allow researchers to potentially access CSRs and individual patient data from their 
clinical trials (https://restoringtrials.org/insitutions-offering-data-access/).  
Conclusions 
Oseltamivir appears to play a causal role in the development of psychiatric adverse events 
however the absolute risk is small. CSRs provide a much richer database of information on 
adverse events compared to other sources, including publications. Our methods can be used 
to fully utilize this information and provide additional insights into the unintended effects of 
pharmaceutical interventions. This has great relevance to future new drugs and their 
evaluation, especially for important early warnings of AEs.  
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Box:  Excerpt of Clinical Study Report on adverse events reported in oseltamivir trial 
WV15825 to illustrate the information available on each adverse event reported 
 
 
  
Table 1: Study details on the four prophylaxis trials of oseltamivir for influenza 
Trial 
 
WV15825(16) WV15673/97(17) WV15708 WV15799(18) 
Unit of 
randomisation 
 
Individuals (in 
nursing homes) 
Individuals Individuals (in 
nursing homes) 
Households 
Treatment Oseltamivir 75 
mg o.d. for 6 
weeks 
Oseltamivir 75 
mg o.d. or 75 mg 
b.i.d. for 6 weeks 
 
Oseltamivir 75 
mg o.d. for 6 
weeks 
Oseltamivir 75 
mg o.d. for 7 
days 
Sample size 
(safety 
population) 
 
272 placebo 
276 treatment 
519 placebo 
1040 treatment 
182 placebo 
190 treatment 
461 placebo 
494 treatment 
Age group 
 
 
Elderly Adults Elderly Adults and 
adolescents 
Study duration 
 
8 weeks 8 weeks 8 weeks 3 weeks 
Adverse events 
information 
collected 
 
Weeks 3, 6, 8 
and any illness 
visit 
Weekly Weeks 3, 6, 8 
and any illness 
visit 
Daily for 8 days 
then at 21 days 
Psychiatric 
adverse events 
published 
 
No* No Entire study 
unpublished 
No 
*Not reported in the original publication, although they were reported in an erratum(9) 
 
  
Table 2:     Psychiatric adverse event (AEs) types in oseltamivir prophylaxis trials, classified 
by MedDRA 
 Number of AEs 
Psychiatric AE type 
 
Oseltamivir  Placebo 
Confusion 
 
4 2 
Depression 
 
10 4 
Anxiety 
 
4 6 
Psychosis 
 
2 0 
Schizophrenia 
 
1 0 
Bipolar disorder 
 
0 1 
Sleeping disorder 
 
2 0 
Stress symptoms 
 
2 0 
Restlessness 
 
1 0 
Nervousness 
 
1 0 
Suicide ideation 
 
1 0 
Alcohol related 
 
Hallucinations 
 
6 
 
*1 
2 
 
0 
Total 
 
35 15 
*One patient classified as having severe hallucinations in the Oseltamivir group of study 
WV15825 was also classified as having severe depression and severe confusion 
simultaneously. For the purposes of our analysis this was considered to be one psychiatric 
event.  
 
  
Table 3:  Predicted percentage of days affected by psychiatric adverse events (AEs) in 
oseltamivir prophylaxis trials from a nominal logistic regression 
Treatment group 
 
Placebo 
 
Oseltamivir 
Intensity of AE  None Mild Moderate Severe  None Mild Moderate Severe 
Percentage of 
days affected* 
 
99.83 0.11 0.05 0.005 
 
99.51 0.13 0.21 0.15 
*Using these percentages, approximately 290 patient days of treatment with oseltamivir 
would lead to 1 additional day of suffering from a psychiatric AE of any intensity 
  
Figure 1: Psychiatric AEs in two prophylaxis trials of the elderly with oseltamivir taken once 
daily for 6 weeks 
Trial WV15708 
 
Trial WV15825 
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Figure 2: Psychiatric AEs in trial WV15673/97 of oseltamivir taken once daily or twice daily 
for 6 weeks  
 
 
Figure 3: Psychiatric AEs in trial WV15799 of oseltamivir taken once daily for 7 days  
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